Aristocrat Berea: Failed Drug Investigation - OH
Aristocrat Berea Healthcare and Rehabilitation's director of nursing confirmed during an August inspection that administrators conducted "face to face interviews with all the nurses involved" but took no written statements and spoke to no residents during the investigation.
The facility's own policy requires investigators to "interview the resident, the accused, and all witnesses" in cases of suspected misappropriation of resident property. Federal regulations define misappropriation as "the deliberate misplacement, exploitation, or wrongful temporary or permanent use of a resident's belongings or money without the resident's consent."
Two residents were affected by the incomplete investigation. Both were prescribed oxycodone and both were cognitively intact, according to their medical assessments.
Resident 13 had been at the facility since October 2023. Her medical record showed a complex array of conditions including cerebral infarction, congestive heart failure, diabetes, chronic obstructive pulmonary disease, multiple sclerosis, dementia, anxiety disorder, chronic pain syndrome, and psychosis disorder.
She was prescribed oxycodone 5 milligrams every six hours as needed for pain from December 2024 through June 2025. Her prescription was then reduced to every 12 hours as needed. Her cognitive assessment from July showed she was mentally capable of providing testimony about her medication experiences.
Resident 22 arrived at the facility in January 2025 with diagnoses that included antiphospholipid syndrome, insomnia, anxiety disorder, major depressive disorder, lupus anticoagulant syndrome, fibromyalgia, osteoarthritis, anemia, and depression. She was prescribed oxycodone 5 milligrams every eight hours as needed for pain.
Her July cognitive assessment also showed she was mentally intact and capable of participating in an investigation.
When inspectors asked the director of nursing why no written statements were taken during the investigation, she explained that staff "just did face to face interviews with all the nurses involved to help make the determination if wrongdoing happened."
The director confirmed the facility had no documentation from interviews with potential resident victims.
This approach violated the facility's own investigation protocol, which states that evidence of investigations "should be documented in accordance with quality assurance protocols." The policy specifically requires interviewing witnesses, defined as "anyone who witnessed or heard the incident and employees who worked closely with the accused employees and/or alleged victim the day of the incident."
Federal inspectors reviewed the facility's abuse and misappropriation policy, dated May 2025, which acknowledges that residents have the right to be free from misappropriation of their property. The policy commits the facility to investigate "all alleged violations involving abuse, neglect, misappropriation of resident property, exploitation or mistreatment" and to ensure that people who report incidents are protected from retaliation.
The 137-bed facility's investigation failures came to light during a complaint inspection conducted in August. Federal regulators classified the violation as causing "minimal harm or potential for actual harm" but noted it represented systematic non-compliance with investigation requirements.
Oxycodone is a controlled substance that requires careful tracking and documentation. Nursing facilities must account for every dose dispensed and maintain detailed records of narcotic administration. When allegations arise involving controlled substances, thorough investigations become critical both for resident safety and regulatory compliance.
The two affected residents represented a significant portion of those reviewed during the inspection. Inspectors examined three residents for misappropriation concerns and found investigation failures affected two of them.
Neither resident's medical record indicated any awareness of the investigation that concerned their medications. The facility provided no documentation showing administrators explained the allegations to the residents or sought their input about their medication experiences.
The inspection occurred nearly nine months after Resident 22's admission and almost two years after Resident 13 arrived at the facility. Both women had been receiving oxycodone prescriptions for months when the investigation took place.
Resident 13's prescription history showed her oxycodone dosing was reduced from every six hours to every 12 hours in June 2025, around the time the investigation may have been conducted. The timing suggests the medication changes could have been related to the allegations under investigation.
The facility's policy emphasizes that misappropriation investigations must be comprehensive. The protocol requires gathering testimony from multiple sources to establish facts and determine whether wrongdoing occurred. By limiting interviews to nursing staff and avoiding resident testimony, administrators potentially missed crucial information about medication administration patterns.
Federal regulations require nursing homes to investigate allegations thoroughly and document their findings. The regulations exist because residents in long-term care settings are particularly vulnerable to exploitation and abuse. Many residents depend entirely on facility staff for their medications and have limited ability to monitor whether they receive prescribed doses.
Cognitive assessments showing both residents were mentally intact made their exclusion from the investigation particularly problematic. Unlike residents with dementia or severe cognitive impairment, these women could have provided detailed accounts of their medication experiences and any concerns about their care.
The investigation's scope remains unclear from the inspection report. Inspectors did not document how many nurses were interviewed, what allegations prompted the investigation, or what conclusions administrators reached. The director of nursing's confirmation that the facility made "the determination if wrongdoing happened" suggests the investigation was completed, but without resident input.
Aristocrat Berea Healthcare and Rehabilitation operates as part of a larger network of nursing facilities. The Berea location serves residents from the Cleveland metropolitan area and surrounding communities in northeastern Ohio.
The facility's investigation failures highlight broader challenges in nursing home oversight. Residents prescribed controlled substances like oxycodone represent particularly vulnerable populations who depend on facility staff for proper medication management and protection from potential misappropriation.
Without interviewing the residents whose medications were in question, administrators could not fully assess whether misappropriation occurred or ensure that proper safeguards were in place to prevent future incidents.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Aristocrat Berea Healthcare and Rehabilitation from 2025-08-30 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: June 20, 2026 · Our methodology
ARISTOCRAT BEREA HEALTHCARE AND REHABILITATION in BEREA, OH was cited for violations during a health inspection on August 30, 2025.
Both were prescribed oxycodone and both were cognitively intact, according to their medical assessments.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.